Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced today that its management team will participate in two prominent investor conferences in March 2026, providing an opportunity to highlight the company's recent commercial milestone and advancing pipeline. Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, from 11:10 a.m. to 11:40 a.m. ET at the Boston Marriott Copley Place in Boston. Additionally, management will participate in one-on-one meetings at the Barclays 28th Annual Healthcare Conference, scheduled for March 10-12, 2026, at the Loews Miami South Beach Hotel in Miami Beach.
The conferences come on the heels of Tonix's recent U.S. Food and Drug Administration (FDA) approval of TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8 mg), the first new treatment for fibromyalgia in over 15 years. This approval marks a significant milestone for the company and underscores its commitment to addressing high unmet medical needs in central nervous system (CNS) disorders. Tonix is a fully-integrated, commercial-stage biotechnology company focused on CNS and immunology treatments. Its CNS commercial infrastructure supports marketed products, including acute migraine treatments Zembrace® SymTouch® and Tosymra®.
Beyond TONMYA's approval, Tonix is maximizing the science behind the drug through Phase 2 clinical trials evaluating its potential in major depressive disorder and acute stress disorder. The company's CNS pipeline also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare genetic disorder. In immunology, Tonix is advancing programs such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection. These programs highlight the company's diversified approach to tackling conditions with significant patient need.
Investor conferences provide a platform for Tonix to communicate its strategic vision and recent achievements to the financial community. The presentations and meetings are expected to cover the commercial launch of TONMYA, progress in clinical development, and the company's overall pipeline strategy. As Tonix transitions from a development-stage to a commercial-stage entity, its participation in these high-profile events is crucial for building investor confidence and visibility. For more information and updates on the company, visit its newsroom.
The TD Cowen and Barclays conferences are among the largest healthcare investment gatherings, attracting institutional investors, analysts, and industry leaders. Tonix's presence at both events underscores its commitment to engaging with the investment community and advancing its mission to develop innovative therapies for CNS and immunological diseases.
